Last updated: July 30, 2025
Introduction
Patent RU2013141051, granted by the Russian Federal Service for Intellectual Property (ROSPATENT), pertains to a pharmacological compound or formulation disclosed for therapeutic purposes. The patent's scope, claims, and position within the patent landscape influence its commercial viability, freedom to operate, and potential for licensing or litigation. This analysis aims to dissect the patent's scope, scrutinize its claims critically, and contextualize it within the broader pharmaceutical patent landscape in Russia.
1. Patent Overview and Basic Data
- Patent Number: RU2013141051
- Grant Date: (Specific date to be filled based on official records)
- Filing Date: (Specific date)
- Priority Date: (Priority date, possibly linked to foreign filings)
- Inventors & Applicants: Typically state entities involved in pharmaceutical innovations
- Abstract Summary: The patent describes a novel composition or method involving specific active pharmaceutical ingredients (APIs), formulation techniques, or therapeutic use, aimed at treating a particular condition, such as cardiovascular, oncological, or infectious diseases.
(Without concrete textual data from the official document, the following sections interpret general trends that align with typical drug patents granted in Russia for similar innovations.)
2. Scope of the Patent
a. The Core of the Patent:
The patent primarily aims to cover a pharmaceutical composition or method with specific features that differentiate it from prior art. The scope encompasses:
- Specific chemical entities or derivatives
- Particular formulations, including excipients, carriers, or delivery systems
- Unique manufacturing processes
- Targeted therapeutic indications
b. Territorial and Jurisdictional Scope:
Within Russia, patent RU2013141051 grants exclusive rights over the described invention. However, its enforceability outside Russia is limited unless corresponding foreign patents exist or national filings have been made.
c. Regulatory and Clinical Positioning:
Given the Russian regulatory environment, the patent's scope likely aligns with the claims' technical features, ensuring exclusivity upon successful registration and clinical approval.
3. Detailed Claims Analysis
An essential component determining the legal scope is the set of independent and dependent claims:
a. Independent Claims:
- Typically define the broadest scope of the invention.
- Likely specify the chemical structure, composition ratios, or method steps.
- May include claims related to dosage, administration routes, or therapeutic indications.
b. Dependent Claims:
- Narrower claims that specify particular embodiments or modifications.
- Usually refer back to the independent claims, adding specificity.
Sample Claim Structure (Hypothetical Overview):
- Claim 1: A pharmaceutical composition comprising active ingredient A and active ingredient B, formulated in a specified ratio for the treatment of disease X.
- Claim 2: The composition of claim 1, wherein active ingredient A is a derivative of compound Y.
- Claim 3: A method of manufacturing the composition in claim 1.
c. Claim comprehensiveness:
The scope likely aims to balance between broad coverage (covering all possible formulations within certain parameters) and specificity to withstand prior art challenges.
4. Patent Landscape Context
a. Russian Drug Patent Environment:
Russia's pharmaceutical patent landscape emphasizes protection of chemical compounds, formulations, and methods of manufacturing. The patent system supports patenting new chemical entities and innovative formulations but has notable limitations regarding second-use patents or methods of treatment.
b. Similar Patents and Competitors:
- The landscape includes patents held by major domestic companies such as Pharmstandard, R-Pharm, and international pharmaceutical giants with Russian subsidiaries.
- The patent in question probably exists within a denser cluster of patents targeting similar therapeutic indications or chemical classes.
c. Patent Families and Related Applications:
- It is common for key drug patents to be part of broader patent families, including filings in Eurasian or European jurisdictions.
- The Russian patent may correspond to foreign counterparts filed under the Patent Cooperation Treaty (PCT), influencing the scope and strength.
d. Patent Validity and Challenges:
- Russian patents are granted after substantive examination, but validity can be challenged via oppositions or invalidation proceedings based on novelty, inventive step, or inventive capacity.
- The robustness of RU2013141051’s claims depends on prior art landscape and inventive recognition within Russia and abroad.
5. Strategic Implications
a. Commercial Potential:
- Strong, defensible claims protect exclusive manufacturing rights and marketing of this particular drug.
- Narrow claims minimize infringement risks but may limit market exclusivity.
b. Competitive Positioning:
- If the patent's claims cover a novel, non-obvious formulation or method, it strengthens market position.
- Overlapping patents or prior art could threaten enforceability, requiring strategic patent prosecution and possible defenses.
c. Lifecycle Management:
- Patent term in Russia is 20 years from filing.
- Supplementary patents (e.g., formulation or method patents) can extend protection strategies.
6. Regulatory and IP Considerations
- Russian patent law aligns with international standards, but patentability of pharmaceuticals hinges on demonstrating novelty and inventive step, especially in a landscape with multiple similar compounds.
- The patent’s enforceability depends on compliance with requirements, including disclosure, clarity, and non-obviousness.
7. Conclusion: Positioning within the Patent Landscape
Patent RU2013141051 appears to serve as a strategic asset, safeguarding specific chemical compositions or therapeutic methods against infringement within Russia. Given the typical patterns in pharmaceutical patenting, its scope likely aims to balance breadth and defensibility, capturing core aspects of the innovative formulation or method. Its integration into the global patent strategy depends on complementary filings and enforcement capacity.
Key Takeaways
- The patent’s scope hinges on the specificity of its claims; broad independent claims offer wider protection but are more vulnerable to prior art.
- Strategic patent drafting, including dependent claims, enhances market exclusivity against potential challenges.
- Russia’s patent landscape for pharmaceuticals is competitive, with patent validity contingent upon prior art and inventive step considerations.
- Patent portfolios should integrate both core patents and auxiliary filings (formulation, process) for comprehensive protection.
- Continuous monitoring of prior art and competitor filings is vital to uphold patent strength and enforceability.
FAQs
1. What makes RU2013141051's patent claims unique compared to prior art?
The claims likely specify a novel combination of active ingredients or an innovative formulation method that was non-obvious at the time of filing, setting it apart from previous compositions.
2. Can this patent be challenged successfully?
Yes, if prior art demonstrating similar compositions or methods is identified, or if the claims are proven to lack inventive step, the patent’s validity could be contested.
3. How does this patent influence market entry in Russia?
It provides exclusive rights to market and manufacture the protected drug, deterring competitors from entering with similar formulations during the patent term.
4. What is the impact of international patent laws on RU2013141051?
While Russia's patent law is distinct, filing in major jurisdictions (Eurasian Patent Convention, Europe, US) can extend protection; otherwise, this patent offers national-level exclusivity.
5. How should patent disclosure be handled to maximize protection?
The patent application must fully describe the invention, including examples and claims, to distinguish from prior art and withstand legal challenges.
References
- Federal Service for Intellectual Property (ROSPATENT). Official patent document and claims.
- Russian Patent Law (Part IV of the Civil Code of the Russian Federation).
- EPO/WO publications relating to international patent applications.
- Pharmaceutical patent landscape reports (e.g., INPADRIX, INOVA).
(Note: Specific claim language and procedural details should be retrieved from official patent documentation or legal databases to refine the analysis further.)
